证券日报网讯11月28日晚间，普洛药业（000739）发布公告称，不存在逾期担保。 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-73 普洛药业股份有限公司 关于对下属公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2025 年 11 月 5 日，普洛药业股份有限公司（以下简称"公司"）与中 国银行股份有限公司东阳支行（以下简称"中国银行"）签订《保证合同》（合 同编号：横店 2025 年人保字 176 号），同意为公司全资子公司浙江普洛家园药 业有限公司与中国银行签署的《流动资金借款合同》（合同编号：横店 2025 年 人借字 176 号）中的 2,000 万元流动资金贷款提供连带责任保证，担保期限 12 个月。 2、2025 年 11 月 6 日，公司与中国银行签订《保证合同》（合同编号：横 店 2025 年人保字 182 号），同意为公司全资子公司浙江普洛得邦制药有限公司 与中国银行签署的《流动资金借款合同》（合同编号：横店 2025 年人借字 182 号）中的 5,000 万元流动资金贷款提供连带责任保证，担保期限 10 个月。 3、2025 年 11 月 19 日，公司与中 ...

Core Viewpoint - The company, Prolo Pharmaceutical, announced that its drug, Dihydrosulfonic Acid Adenosylmethionine Enteric-Coated Tablets, is expected to be approved in November 2024 and is currently expanding its market presence in the Beijing-Tianjin-Hebei "3+N" alliance and Guangdong alliance [1] Group 1 - The drug is set to receive approval in November 2024 [1] - The company has already won bids in the Beijing-Tianjin-Hebei "3+N" alliance and Guangdong alliance [1] - The company is in the process of rapidly expanding its market [1]

普洛药业股份有限公司 关于第一期员工持股计划存续期即将届满的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：000739 证券简称：普洛药业 公告编号：2025-72 4、2024 年 3 月 6 日，公司召开第九届董事会第四次会议，审议通过了《关 于公司第一期员工持股计划存续期展期的议案》，同意将公司第一期员工持股计 划存续期展期 24 个月，即存续期展期至 2026 年 5 月 28 日。 具体内容详见公司分别于 2019 年 6 月 12 日、2020 年 6 月 11 日、2022 年 3 月 10 日、2024 年 3 月 8 日刊登在《证券时报》和巨潮资讯网（www.cninfo.com.cn） 上披露的相关公告。 5、截至本公告日，公司第一期员工持股计划通过集中竞价交易方式累计减 持 11,100,000 股；尚持有公司股份 21,564,016 股，占公司目前总股本的 1.86%。 本次员工持股计划持有公司股份均未出现或用于抵押、质押、担保等情形。 普洛药业股份有限公司(以下简称"公司")分别于 2019 年 5 月 10 ...

Core Insights - The establishment of the medical beauty and cosmetics division by Pro Pharmaceutical (普洛药业) on November 4, 2024, aims to enhance quality of life with a focus on product and client development in this sector [2]. Group 1: Business Development - The medical beauty and cosmetics raw materials business is a key development direction for the company, currently in the phase of developing new products and clients [2]. - The company anticipates that the market size for this business segment will experience rapid growth in the coming years [2].

Core Viewpoint - The company has successfully launched its product, Dihydrosilyl Adenosine Methionine Enteric-Coated Tablets, which is recognized for its clear pharmacological mechanism, high safety, and good clinical efficacy, positioning it as a preferred treatment for liver diseases [2]. Company Summary - The product received approval for market launch in November 2024 and is currently expanding its market presence [2]. - The company has secured bids in the Beijing-Tianjin-Hebei "3+N" alliance and the Guangdong alliance, indicating a strategic approach to market penetration [2].

Policy Developments - Shanghai government issued measures to promote high-quality development in the pharmaceutical industry, focusing on key areas such as cell and gene therapy, rare diseases, high-quality first generic drugs, and AI medical devices [2] Drug Approvals - Yipinhong received a drug registration certificate for Levodopa oral solution, aimed at treating mild to moderate Alzheimer's symptoms, with an estimated sales scale of approximately 100.21 million RMB in 2024 [4] - Prolo Pharma obtained a drug registration certificate for Cefdinir dry suspension, which is the first generic drug approved in China for this formulation, with a projected market size of 760 million RMB in 2024 [5] - Haichuang Pharma's HP518 tablet, a PROTAC drug for advanced prostate cancer, received clinical trial approval, with no similar products currently approved in the market [6] Market Activity - Dae Oriental announced plans to transfer 80% of its subsidiary Jinhua Lianji's equity for 1 RMB and related debts for approximately 5.8 million RMB [8] - Jichuan Pharma plans to repurchase shares worth between 25 million and 50 million RMB, with a maximum repurchase price of 38 RMB per share [9] Industry Trends - JD's data indicated a 22-fold year-on-year increase in sales of flu medications during the current flu season, with significant spikes in demand for specific drugs like Oseltamivir and Sufentanil [11] - The respiratory virus testing orders on JD's platform increased by 66%, with a positivity rate of 68.2% [11] Tax Compliance - Shenqi Pharma's subsidiary paid approximately 16.67 million RMB in overdue corporate income tax and penalties [13] Regulatory Issues - Former deputy director of the National Medical Products Administration, Chen Shifei, was arrested for bribery, highlighting ongoing regulatory scrutiny in the pharmaceutical sector [15]

Group 1 - The core focus of the company is on the development of its medical beauty cosmetics raw materials business, which is considered a key growth area [1] - The company is currently in the stage of developing new products and acquiring new customers for this business segment [1] - The market size for this business is expected to achieve rapid growth in the coming years [1]

Group 1 - The core focus of the company is on the development of its medical beauty cosmetics raw materials business, which is considered a key growth area [1] - The company is currently in the stage of developing new products and acquiring new customers for this business segment [1] - The market size for this business is expected to achieve rapid growth in the coming years [1]

Group 1 - Heptagon Pharma announced an update to its global strategic collaboration with AstraZeneca, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) [1] - AstraZeneca will nominate research projects to Heptagon Pharma annually for the next four years, granting them licensing options for these projects [1] - The collaboration reflects the strengthening partnership between Heptagon Pharma and AstraZeneca, highlighting the integration of Chinese biotech companies into the global pharmaceutical ecosystem [1] Group 2 - Prolog Pharma's subsidiary received a drug registration certificate for Cefdinir dry suspension, marking it as the first domestic generic drug approved under the consistency evaluation of quality and efficacy [2] - This approval allows Cefdinir to participate in national medical insurance negotiations, enhancing its market competitiveness [2] Group 3 - Sinovac's recombinant shingles vaccine has received clinical trial approval from the National Medical Products Administration, targeting individuals aged 40 and above [3] - The market for shingles vaccines in China is currently limited, with existing products facing low public willingness for vaccination [3] Group 4 - AstraZeneca announced a $2 billion investment to expand its manufacturing operations in Maryland, marking its fourth major manufacturing investment in the U.S. this year [4] - The company plans to invest $50 billion in the U.S. by 2030 to enhance its manufacturing and R&D capabilities, which is expected to create tens of thousands of jobs [4] Group 5 - Mandi International has submitted its application for listing on the Hong Kong Stock Exchange, focusing on skin health and weight management solutions, with its core brand being a hair loss treatment product [5] - Mandi has ranked first in the Chinese hair loss medication market for ten consecutive years, holding a market share of 57% in 2024 [5] - The company's revenue is highly dependent on a single product, making its IPO progress a point of interest for investors [5]